Home

Vistagen to Present at The Menopause Society 2025 Annual Meeting

via Business Wire

Posters Highlight New Insights into PH80’s Effects on Brain and Autonomic Activity

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Meeting in Orlando, Florida, on Thursday, October 23, 2025.

PH80 is Vistagen’s novel, non-systemic, non-hormonal, rapidly acting clinical stage pherine product candidate being evaluated as a potential treatment of vasomotor symptoms (hot flashes) due to menopause. The Company’s posters will discuss data from nonclinical and Phase 1 clinical studies of PH80.

Poster Presentations:

Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern Time

Title: PH80 Nasal Spray: In Vitro Receptor Binding, Effects on Reproductive Organs in Mice, and Pharmacokinetic Profile in Humans— A Potential, Novel, Rapid, Non-hormonal Treatment for Vasomotor Symptoms due to Menopause

Authors: Louis Monti, MD, PhD; Ross A. Baker, PhD; Rita Hanover, PhD

Poster Number: P-124

Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern Time

Title: PH80 Nasal Spray Effects on Brain and Autonomic Activity: A Potential, Novel, Rapid, Non-hormonal, Treatment for Vasomotor Symptoms due to Menopause

Authors: Louis Monti, MD, PhD; Ross A. Baker, PhD; Rita Hanover, PhD

Poster Number: P-13

About Vistagen

Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly trigger olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved.

Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, vasomotor symptoms (hot flashes) associated with menopause and premenstrual dysphoric disorder. Connect at www.Vistagen.com

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements related to the treatment potential of PH80. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Risks that may impact the outcome of these forward-looking statements are more fully discussed in the section entitled “Risk Factors” in Vistagen’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025, and Quarterly Report on Form 10-Q for the period ended June 30, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Vistagen’s other filings with the U.S. Securities and Exchange Commission (SEC). Vistagen’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen’s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.

Contacts